- Home
- WRLD vs RGNX Comparison
WRLD vs RGNX Comparison
Compare WRLD & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WRLD | RGNX |
|---|---|---|
| Founded | 1962 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.6M | 761.9M |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | WRLD | RGNX |
|---|---|---|
| Price | $133.12 | $8.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.75 |
| AVG Volume (30 Days) | 110.7K | ★ 810.3K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $564,841,465.00 | $10,393,000.00 |
| Revenue This Year | N/A | $58.79 |
| Revenue Next Year | $6.51 | $29.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $104.99 | $5.04 |
| 52 Week High | $185.48 | $16.19 |
Technical Indicators
Market Signals| Indicator | WRLD | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 40.83 |
| Support Level | $123.42 | $7.83 |
| Resistance Level | $151.20 | $9.28 |
| Average True Range (ATR) | 6.91 | 0.64 |
| MACD | -0.24 | 0.20 |
| Stochastic Oscillator | 29.29 | 23.57 |
Price Performance
Historical ComparisonAbout WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.